Piqray (Alpelisib) 150mg 56 Tablets | Novartis Hong Kong Original | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

Share
Product description

Generic Information: Piqray (Alpelisib) — Novartis Hong Kong Original

This is the Hong Kong presentation of Piqray, the Novartis original alpelisib brand: English-labeled cartons of 150 mg film-coated tablets packed as a 28-day supply — 56 tablets in two 14-day blister cards, sized to the standard dose of two tablets each morning. Hong Kong approved Piqray at the end of 2020, and the medicine soon became reachable for mainland patients through the Greater Bay Area "Hong Kong-Macao drug and device use" scheme, with the first doses given at the University of Hong Kong-Shenzhen Hospital. For patients across Asia, the HK pack is the closest regulated-market original — international labeling, Novartis channel, and no translation barrier.

What Is Piqray (Alpelisib) Used For?

Piqray is indicated, with fulvestrant, for HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer that has progressed after endocrine therapy, in postmenopausal women and in men. The mutation context is decisive: roughly 40% of HR+/HER2- advanced breast cancers carry a PIK3CA mutation (approaching half in Chinese patient series), and that mutation keeps the PI3K growth pathway lit even while hormone therapy is working everywhere else. Treatment starts only after a validated PIK3CA result from tumor tissue or blood plasma.

How Does Piqray (Alpelisib) Work?

Alpelisib selectively inhibits PI3K alpha, quieting the mutated PIK3CA-driven growth signal; fulvestrant simultaneously degrades the estrogen receptor the tumor still depends on. The combination's credential is the SOLAR-1 trial: median progression-free survival of 11.1 months versus 5.7 months with fulvestrant alone in PIK3CA-mutated disease, and a 7.9-month extension of median overall survival. Intracranial-friendly pharmacology aside, the drug's value shows most clearly in visceral disease, where the survival signal was strongest.

Indications of Piqray (Hong Kong)

The Hong Kong label mirrors the international core: combined use with fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer after progression on an endocrine-based regimen. Note the brand boundary within Novartis' own portfolio — the PROS overgrowth indication for alpelisib belongs to Vijoice, not Piqray, and the two are dosed on entirely different schedules.

Dosage and Administration

Standard dosing is 300 mg once daily — two 150 mg tablets swallowed whole with food — which makes the 56-tablet HK carton exactly one treatment month. The dose-reduction ladder runs 300 mg to 250 mg daily (one 200 mg plus one 50 mg tablet) and then 200 mg daily (one 200 mg tablet) for manageable toxicity. Fulvestrant is given 500 mg intramuscularly on days 1, 15 and 29, then monthly. A forgotten dose can be taken with food within nine hours of the scheduled time; later than that, skip and resume normally, and never re-dose after vomiting.

Side Effects of Piqray

Expect and monitor: high blood sugar (the characteristic effect — fasting glucose and HbA1c are tested before and during treatment), diarrhea, mouth sores, rash, tiredness and reduced appetite, plus laboratory shifts in creatinine and liver enzymes. Serious watch-items are severe hypersensitivity, severe skin reactions (Stevens-Johnson syndrome and related), pneumonitis, and embryo-fetal harm — contraception during and after therapy is non-negotiable. Most effects are manageable with early reporting, dose holds and standard supportive care; the care team decides between interruption, one-step dose reduction or discontinuation based on severity.

Storage Instructions

Keep the carton below 30°C, dry, out of light, blisters unopened until use. No refrigeration needed. Store away from children, and return expired tablets to a pharmacy for safe disposal.

Why Choose Piqray (HK) from GLT?

The HK presentation is the pragmatic middle path between European originals and generics: Novartis original product, English international labeling, and Hong Kong regulatory standing that hospitals and clinics across the region recognize instantly — often at markedly lower cost than US-channel supply. GLT ships sealed HK cartons with batch documentation and pre-dispatch photographs, serves both families and institutions, and answers every message personally on WhatsApp +86 15234153837 or [email protected]. If stock of the HK pack is tight, we will say so plainly and offer the German original or verified alternatives instead.

How to Order Piqray (Alpelisib)

Message WhatsApp +86 15234153837 or email [email protected] with the pack size and quantity you need. You receive a written quotation with shipping and payment options — usually within one working day — and after confirmation GLT dispatches with full export paperwork. Monthly recurring orders can be scheduled in advance so the treatment calendar never breaks; institutions can request CoA and batch images before payment.

FAQ

Is the HK pack the same medicine as the German one? Yes — Novartis original alpelisib 150 mg; only the carton language, pack size and registration market differ.

How many boxes make a month? The 56-tablet carton is exactly 28 days at the standard two-tablets-per-morning schedule.

Can mainland patients use the Hong Kong medicine? Through the Greater Bay Area mechanism the same original has been used at designated mainland hospitals; GLT supplies the HK presentation directly with export documentation for personal and institutional channels.

Does Piqray work without a PIK3CA mutation? No — trials showed benefit confined to mutation carriers; do the test first (tissue or blood).

What monitoring comes with treatment? Fasting glucose and HbA1c at baseline and regularly during therapy, skin and gut symptoms at every review, and immediate assessment for any blistering rash or new cough.

Related Oncology Products

XinKePing 欣可平 (Avatrombopag) 20mg*10 Tablets | Nanjing Hencer China | GLT

XinKePing — API-plus-tablet integrated avatrombopag from Nanjing Hencer Pharmaceutical (Jemcare group), China Mainland

KeZeRui 科瑞泽 (Avatrombopag) 20mg*10 Tablets | Sichuan Kelun China | GLT

KeZeRui — national-procurement avatrombopag from Sichuan Kelun Pharmaceutical, China's integrated API + tablet maker

Zepbound (Tirzepatide) 2.5–15mg/0.5mL Single-Dose Pen | Eli Lilly USA | GLT

Zepbound — Eli Lilly tirzepatide single-dose pen, six US strengths (2.5–15mg/0.5mL) for chronic weight management...

AVATODX (Avatrombopag) 20mg*30 Tablets | Bigbear Pharmaceutical Laos | GLT

AVATODX — avatrombopag 20mg by Bigbear Pharmaceutical (Lao) Co., Ltd., Lao Reg. 06L0985/23, 30-tablet bottle

Olumiant (Baricitinib) 2mg/4mg Tablets | JAK1/JAK2 Inhibitor | Eli Lilly USA | GLT

Eli Lilly's selective JAK1/JAK2 inhibitor for rheumatoid arthritis, atopic dermatitis and severe alopecia areata.

KangQuXin 康曲欣 (Avatrombopag) 20mg*10 Tablets | Beijing Continent Gyre | GLT

KangQuXin — avatrombopag by Beijing Continent Pharmaceutical (Gyre Therapeutics, Nasdaq: GYRE), China Mainland

Orforglipron (LuciOrfor) 0.8–17.2mg Tablets | Laos Generic Oral GLP-1 | GLT

Lucius Pharmaceuticals (Laos) generic orforglipron, 6-dose titration for weight management

Barinat (Baricitinib) 4mg | Generic JAK1/JAK2 Inhibitor | Natco Pharma Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Natco Pharma Limited (India) — an affordable alternative to Olumiant...